Engineered immune cells take aim at Tough-to-Treat blood cancers
NCT ID NCT04836507
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous treatments. Participants receive a single infusion of these engineered cells, and the study aims to find the safest dose and measure how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CRC01 (CAR T-cell therapy targeting CD19)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat B-cell cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Catholic University of Korea Seoul St. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••